These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 28527652)
1. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient. Kanno H; Ishida K; Yamada W; Nishida T; Takahashi N; Mochizuki K; Mizuno Y; Matsuyama K; Takahashi T; Seishima M J Infect Chemother; 2017 Nov; 23(11):774-777. PubMed ID: 28527652 [TBL] [Abstract][Full Text] [Related]
2. Bilateral uveitis and macular edema induced by Nivolumab: a case report. Theillac C; Straub M; Breton AL; Thomas L; Dalle S BMC Ophthalmol; 2017 Dec; 17(1):227. PubMed ID: 29195497 [TBL] [Abstract][Full Text] [Related]
3. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma. Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227 [TBL] [Abstract][Full Text] [Related]
5. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma. Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106 [TBL] [Abstract][Full Text] [Related]
6. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review. Obara K; Masuzawa M; Amoh Y J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490 [TBL] [Abstract][Full Text] [Related]
7. Nivolumab: A Review in Advanced Melanoma. Scott LJ Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912 [TBL] [Abstract][Full Text] [Related]
9. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma. Hanna KS Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250 [TBL] [Abstract][Full Text] [Related]
11. Melanoma patient response to nivolumab treatment for metastatic lung lesions: Multi-OMICS analysis in Project HOPE. Kiyohara Y; Yoshikawa S; Otsuka M; Kondou R; Iizuka A; Nonomura C; Ohshima K; Urakami K; Kusuhara M; Nagashima T; Sugino T; Yamaguchi K; Akiyama Y J Dermatol; 2017 Oct; 44(10):1156-1159. PubMed ID: 28452169 [TBL] [Abstract][Full Text] [Related]
12. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report. Edmondson LA; Smith LV; Mallik A J Oncol Pharm Pract; 2017 Dec; 23(8):629-634. PubMed ID: 27609337 [TBL] [Abstract][Full Text] [Related]
13. Complete response to anti-PD-1 nivolumab in massive skin metastasis from melanoma: efficacy and tolerability in an elderly patient. Sponghini A; Patrucco F; Giorgione R; Farinelli P; Zottarelli F; Rondonotti D; Savoia P Anticancer Drugs; 2017 Aug; 28(7):808-810. PubMed ID: 28489616 [TBL] [Abstract][Full Text] [Related]
14. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study. Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531 [TBL] [Abstract][Full Text] [Related]
15. The safety of nivolumab for the treatment of metastatic melanoma. O'Reilly A; Larkin J Expert Opin Drug Saf; 2017 Aug; 16(8):955-961. PubMed ID: 28679287 [TBL] [Abstract][Full Text] [Related]
16. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940 [TBL] [Abstract][Full Text] [Related]